Eli Lilly and Company [clinicaltrials_resource:7842d4a3c63f3eec2ded513ced2c398f]
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) [clinicaltrials_resource:00a5c4912bf93991edc832b49f5ee72c]Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5PM Eastern time (UTC/GMT - 5 hours, EST [clinicaltrials_resource:00b7f42e935633a3f932c146b6319fe1]Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9AM-5PM Eastern Time (UTC/GMT -5 hours, EST) [clinicaltrials_resource:01ce85e9e39e944b3ec0a831a755b30a]Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Monday - Friday 9am-5pm Eastern time (UTC/GMT - 5 hours, EST) [clinicaltrials_resource:01ed16ee38710d8abee5149e87ca0344]Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) [clinicaltrials_resource:01f7b20fa660b3cfe699f92d5411d194]Call 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559 Mon-Fri 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST [clinicaltrials_resource:0322d661831592e554ca41a6fd03a0eb]Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) [clinicaltrials_resource:0350ef4e71014130f9228989396fe928]Call 1‐877‐CTLILLY (1‐877‐285‐4559) or 1‐317‐615‐4559 Mon ‐ Fri 9 AM ‐ 5 PM Eastern time (UTC/GMT ‐ 5 hours, EST) [clinicaltrials_resource:03811cc54f14ba43dfad3324c2341d31]Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) [clinicaltrials_resource:03fc591fa0e03cd533fe5f47d877b3ea]Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hour, EST) [clinicaltrials_resource:04dfeb70cd2ed75215f6259155213b15]Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hour, EST) [clinicaltrials_resource:05bad80a2efe0944a8e02e84fad6b62a]Call 1-877-CTLILLY (1-877-285-4559) or 1-877-615-4559 Mon-Fri 9 AM - 5 PM Eastern Time (UTC/GMT -5 hours, EST) [clinicaltrials_resource:06c51356b60e55baa2f6a2464425fc85]Call 1-877-CTLILLY (1-877-285-4559) or 1-317 615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) [clinicaltrials_resource:0946878da02033bb7e44d42027a3b6e5]Adam Boxer [clinicaltrials_resource:09b226f993ee36706cda9079ce259692]Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM- 5 PM Eastern time (UTC/GMT - 5 hours, EST) [clinicaltrials_resource:09dfe275d84edd5e8edeb210d07514b8]Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) [clinicaltrials_resource:09f072f166b4cd3651e0a334ddb3002d]Call 1-877-CTLILLY(1-877-285-4559) or 1-317-615-4559 Mon-Fri 9AM - 5PM Eastern time (UTC/GMT - 5 hours, EST) [clinicaltrials_resource:0b66f3ff6a4495c2cf5a867232c4d5eb]Call 1-877-CTLILLY (1-877-285-4599) or 1-317-615-4559 Mon-Fri 9 AM-5 PM Eastern time (UTC/GMT - 5 hours, EST) [clinicaltrials_resource:0b9e7a86de28a3837907646e94aee7bf]Call 1-877-CTLILLY (1-877-285-4559) OR 1-317-615-4559 Mon - Fri 9am - 5pm Eastern Time (UTC/GMT - 5 hours, EST) [clinicaltrials_resource:0d26df49d12c893e9ad655c23d19f533]Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) [clinicaltrials_resource:0d4f208ba359a595aaf285f202f97319]Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST) [clinicaltrials_resource:0d769d355e6ffbfa3a7de6a4bbb78732]Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern time (UCT/GMT - 5 hours, EST) [clinicaltrials_resource:0e82327b520e5f7edf958d4fc5d61250]Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) [clinicaltrials_resource:0f842ebbf2db7df6fbe129d42838d8f8]Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) [clinicaltrials_resource:0faf2dbb12cc132e6f3524ff58fc9417]Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9AM-5PM Eastern Standard time (UTC/GMT - 5 hours, EST) [clinicaltrials_resource:0fc2ffbb7082287d019508d7949a7646]Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) [clinicaltrials_resource:11435be1effc9c26174c5960ff7d748b]Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM- 5 PM Eastern time (UTC/GMT -5 hours, EST) [clinicaltrials_resource:1145c987db833a9f598cea84ebe0bd6f]Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) [clinicaltrials_resource:119aa335a37ac673993edc4d6807384c]Call 1-877-CTLILLY (1-877-285-459) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) [clinicaltrials_resource:119f21d3b8b17abfcf0e8771419c48b9]Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9AM - 5PM Eastern time (UTC/GMT - 5 hours, EST), [clinicaltrials_resource:120a89e511150dd9bbaadf6fa1398fbb]Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern time (UTC/GMT -5 hours, EST) [clinicaltrials_resource:1320b7e651f3592395501ee51a1f6f17]Michael Turik [clinicaltrials_resource:13a4fc22ee6ffbfa3d618173206a0945]Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) [clinicaltrials_resource:1428d25bdea366b724b1c27c329565d9]Call 1-877-CTLILLY(1-877-285-4559) or 1-317-615-4559 Mon - Fri from 9AM-5PM Eastern time (UTC/GMT - 5 hours, EST) [clinicaltrials_resource:14e41ad2b3efb6273c89dcee801ec0ac]Abraham Kroon, MD, PhD [clinicaltrials_resource:1526800ff7e961797416facd992a3b32]Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) [clinicaltrials_resource:16a4c815751c4520a51d3b96b4890997]Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) [clinicaltrials_resource:17107d16b079a1393baf85740cf0091b]Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9AM-5PM Eastern time (UTC/GMT - 5 hours, EST) [clinicaltrials_resource:17e2e18fda7f09af996f5d0169c0d535]Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST) [clinicaltrials_resource:17ecdd4ea912072eb445bce660f1659f]Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 : Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) [clinicaltrials_resource:187123d30e162a98bc29238699e3dec2]
affiliation [clinicaltrials_vocabulary:affiliation]
Study of Tadalafil for the Treatment of Diabetic Patients With Symptoms of Upset Stomach and Delayed Stomach Emptying [clinicaltrials:NCT00050609]Safety and Efficacy of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes Mellitus. [clinicaltrials:NCT00063128]clinicaltrials:NCT00095199clinicaltrials:NCT00097591Comparing Intensive and Standard Training for Human Insulin Inhalation Powder (HIIP) [clinicaltrials:NCT00099515]clinicaltrials:NCT00105989Duloxetine Compared With Placebo in Patients With Generalized Anxiety Disorder [clinicaltrials:NCT00122824]A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder [clinicaltrials:NCT00122837]A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder [clinicaltrials:NCT00122850]Duloxetine Compared With Placebo in the Prevention of Relapse in Generalized Anxiety Disorder [clinicaltrials:NCT00122863]A Study of Duloxetine in the Treatment of Fibromyalgia [clinicaltrials:NCT00125892]PHIRST-1: Tadalafil in the Treatment of Pulmonary Arterial Hypertension [clinicaltrials:NCT00125918]clinicaltrials:NCT00127634Tadalafil in Subjects With Mild to Moderate Hypertension [clinicaltrials:NCT00157326]clinicaltrials:NCT00157339Biomechanical Effects of Duloxetine on Bladder and Sphincter Muscle Function in Women in Pure Genuine Stress Incontinence [clinicaltrials:NCT00190567]Efficacy and Safety of Duloxetine, Placebo and Pelvic Floor Muscle Training in Subjects With Stress Urinary Incontinence [clinicaltrials:NCT00190606]Efficacy and Safety of Duloxetine [clinicaltrials:NCT00190619]To Evaluate the Safety in Patients Taking Duloxetine for Stress Urinary Incontinence [clinicaltrials:NCT00190632]To Evaluate the Safety of Duloxetine in Patients With Stress Urinary Incontinence [clinicaltrials:NCT00190645]Effectiveness and Safety of Duloxetine in Women Experiencing Urinary Leakage Due to Physical Stress and Urge. [clinicaltrials:NCT00190814]Effectiveness of Duloxetine in the Treatment of Stress Urinary Incontinence(Uncontrolled Leakage of Urine) [clinicaltrials:NCT00190827]Study of Duloxetine Versus Placebo in the Treatment of Fibromyalgia Syndrome [clinicaltrials:NCT00190866]Safety and Effectiveness Study of Duloxetine HCl in Women of Different Backgrounds With Stress Urinary Incontinence Who May Also Have Other Various Medical Conditions. [clinicaltrials:NCT00190905]A Trial for Patients With Gestational Trophoblastic Disease [clinicaltrials:NCT00190918]clinicaltrials:NCT00190983Evaluate Safety and Efficacy of Duloxetine in Predominant Stress Urinary Incontinence [clinicaltrials:NCT00190996]Duloxetine in the Treatment of Stress Urinary Incontinence. [clinicaltrials:NCT00191087]Open Label Phase III Duloxetine Study for Stress Urinary Incontinence [clinicaltrials:NCT00191204]A Randomized Study Evaluating the Feasibility and Activity of Three Different Combination With Gemcitabine as First Line Therapy for Non Small Cell Lung Cancer [clinicaltrials:NCT00191490]A Randomized Double Blind Study Evaluating Duloxetine in Outpatients With MDD and Pain [clinicaltrials:NCT00191919]Duloxetine Versus Placebo in the Treatment of FMS [clinicaltrials:NCT00233025]To Determine How Effective Duloxetine is in Treating Women 65 Years and Older With Symptoms of Stress Urinary Incontinence, or With a Combination of Stress Urinary Incontinence and Urge Urinary Incontinence Symptoms [clinicaltrials:NCT00244296]clinicaltrials:NCT00297401clinicaltrials:NCT00320541clinicaltrials:NCT00322621clinicaltrials:NCT00325364A Study of Visual Effects of Erectile Dysfunction Medications Dosed Daily for Six Months [clinicaltrials:NCT00333281]clinicaltrials:NCT00343291clinicaltrials:NCT00355849
collaborator [clinicaltrials_vocabulary:collaborator]
Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Recurrent, Advanced, or Metastatic Endometrial Cancer [clinicaltrials:NCT00003669]Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer [clinicaltrials:NCT00003670]Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast Cancer [clinicaltrials:NCT00006459]Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer. [clinicaltrials:NCT00034125]A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer [clinicaltrials:NCT00034268]ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer [clinicaltrials:NCT00034463]A Phase IIb Study to Determine the Efficacy and Safety of the Study Drug in Patients With Severe Sepsis [clinicaltrials:NCT00034476]A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer. [clinicaltrials:NCT00034489]A Trial of ALIMTA (Pemetrexed) Plus Irinotecan in Patients Who Have Been Previously Treated For Metastatic Colorectal Cancer. [clinicaltrials:NCT00034502]Olanzapine Versus Active Comparator in the Treatment of Bipolar I Disorder [clinicaltrials:NCT00034580]A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium [clinicaltrials:NCT00034593]Comparing 3 Schedules of Alimta Plus Gemzar [clinicaltrials:NCT00034606]A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer. [clinicaltrials:NCT00034619]Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia [clinicaltrials:NCT00034801]A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas. [clinicaltrials:NCT00035035]A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium [clinicaltrials:NCT00035061]Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis [clinicaltrials:NCT00035256]The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression [clinicaltrials:NCT00035321]EVA: Evista Alendronate Comparison [clinicaltrials:NCT00035971]A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury [clinicaltrials:NCT00036062]Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia [clinicaltrials:NCT00036088]Duloxetine Versus Placebo in the Prevention of Relapse of Major Depressive Disorder [clinicaltrials:NCT00036309]Subject Information and Consent Form F1J-US-HMCB Duloxetine Once-Daily Dosing Versus Placebo in Patients With Major Depression and Pain [clinicaltrials:NCT00036335]Efficacy and Safety of Twice-Daily Insulin Lispro Low Mixture Compared to a Once-Daily Long Acting Insulin Comparator in Patients Who Have Been Using One or More Oral Antihyperglycemic Agents Without Insulin [clinicaltrials:NCT00036504]ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma. [clinicaltrials:NCT00040625]Open-Label Treatment With Duloxetine Hydrochloride Once-Daily Dosing for Evaluation of Stabilization Dose in Patients With Major Depression [clinicaltrials:NCT00042562]Dose Escalation, Double-Blind Treatment With Duloxetine Hydrochloride Once Daily Dosing for Evaluation of Safety in Major Depression [clinicaltrials:NCT00042575]A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas. [clinicaltrials:NCT00042666]A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer. [clinicaltrials:NCT00042679]The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes [clinicaltrials:NCT00044148]The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder [clinicaltrials:NCT00044187]Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes [clinicaltrials:NCT00044395]Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes [clinicaltrials:NCT00044408]Treatment of Peripheral Neuropathy in Patients With Diabetes [clinicaltrials:NCT00044421]The Study of Drotrecogin Alfa (Activated) in a Subpopulation of Adult Patients With Severe Sepsis [clinicaltrials:NCT00045760]Combined Use of Teriparatide and Raloxifene in Postmenopausal Women With Osteoporosis [clinicaltrials:NCT00046137]Investigation of the Efficacy and Safety of Drotrecogin Alfa (Activated) in Pediatric Severe Sepsis [clinicaltrials:NCT00049764]A Trial of Heparin in Patients With Severe Sepsis Who Are Undergoing Treatment With Drotrecogin Alfa (Activated) [clinicaltrials:NCT00049777]Olanzapine Versus Placebo in the Treatment of Mania in Adolescents With Bipolar I Disorder [clinicaltrials:NCT00050206]Study of Tadalafil for the Treatment of Diabetic Patients With Symptoms of Upset Stomach and Delayed Stomach Emptying [clinicaltrials:NCT00050609]
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
organization [clinicaltrials_vocabulary:organization]
Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Recurrent, Advanced, or Metastatic Endometrial Cancer [clinicaltrials:NCT00003669]Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer [clinicaltrials:NCT00003670]Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast Cancer [clinicaltrials:NCT00006459]Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer. [clinicaltrials:NCT00034125]A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer [clinicaltrials:NCT00034268]ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer [clinicaltrials:NCT00034463]A Phase IIb Study to Determine the Efficacy and Safety of the Study Drug in Patients With Severe Sepsis [clinicaltrials:NCT00034476]A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer. [clinicaltrials:NCT00034489]A Trial of ALIMTA (Pemetrexed) Plus Irinotecan in Patients Who Have Been Previously Treated For Metastatic Colorectal Cancer. [clinicaltrials:NCT00034502]Olanzapine Versus Active Comparator in the Treatment of Bipolar I Disorder [clinicaltrials:NCT00034580]A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium [clinicaltrials:NCT00034593]Comparing 3 Schedules of Alimta Plus Gemzar [clinicaltrials:NCT00034606]A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer. [clinicaltrials:NCT00034619]Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia [clinicaltrials:NCT00034801]A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas. [clinicaltrials:NCT00035035]A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium [clinicaltrials:NCT00035061]Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis [clinicaltrials:NCT00035256]The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression [clinicaltrials:NCT00035321]EVA: Evista Alendronate Comparison [clinicaltrials:NCT00035971]A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury [clinicaltrials:NCT00036062]Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia [clinicaltrials:NCT00036088]Duloxetine Versus Placebo in the Prevention of Relapse of Major Depressive Disorder [clinicaltrials:NCT00036309]Subject Information and Consent Form F1J-US-HMCB Duloxetine Once-Daily Dosing Versus Placebo in Patients With Major Depression and Pain [clinicaltrials:NCT00036335]Efficacy and Safety of Twice-Daily Insulin Lispro Low Mixture Compared to a Once-Daily Long Acting Insulin Comparator in Patients Who Have Been Using One or More Oral Antihyperglycemic Agents Without Insulin [clinicaltrials:NCT00036504]ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma. [clinicaltrials:NCT00040625]Open-Label Treatment With Duloxetine Hydrochloride Once-Daily Dosing for Evaluation of Stabilization Dose in Patients With Major Depression [clinicaltrials:NCT00042562]Dose Escalation, Double-Blind Treatment With Duloxetine Hydrochloride Once Daily Dosing for Evaluation of Safety in Major Depression [clinicaltrials:NCT00042575]A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas. [clinicaltrials:NCT00042666]A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer. [clinicaltrials:NCT00042679]The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes [clinicaltrials:NCT00044148]The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder [clinicaltrials:NCT00044187]Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes [clinicaltrials:NCT00044395]Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes [clinicaltrials:NCT00044408]Treatment of Peripheral Neuropathy in Patients With Diabetes [clinicaltrials:NCT00044421]The Study of Drotrecogin Alfa (Activated) in a Subpopulation of Adult Patients With Severe Sepsis [clinicaltrials:NCT00045760]Combined Use of Teriparatide and Raloxifene in Postmenopausal Women With Osteoporosis [clinicaltrials:NCT00046137]Investigation of the Efficacy and Safety of Drotrecogin Alfa (Activated) in Pediatric Severe Sepsis [clinicaltrials:NCT00049764]A Trial of Heparin in Patients With Severe Sepsis Who Are Undergoing Treatment With Drotrecogin Alfa (Activated) [clinicaltrials:NCT00049777]Olanzapine Versus Placebo in the Treatment of Mania in Adolescents With Bipolar I Disorder [clinicaltrials:NCT00050206]Study of Tadalafil for the Treatment of Diabetic Patients With Symptoms of Upset Stomach and Delayed Stomach Emptying [clinicaltrials:NCT00050609]
source [clinicaltrials_vocabulary:source]
Eli Lilly and Company [clinicaltrials_resource:7842d4a3c63f3eec2ded513ced2c398f]
Bio2RDF identifier
7842d4a3c63f3eec2ded513ced2c398f
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:7842d4a3c63f3eec2ded513ced2c398f
organization [clinicaltrials_vocabulary:organization]
identifier
clinicaltrials_resource:7842d4a3c63f3eec2ded513ced2c398f
title
Eli Lilly and Company
@en
type
label
Eli Lilly and Company [clinicaltrials_resource:7842d4a3c63f3eec2ded513ced2c398f]
@en